Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future

Autoři

ŘIHÁČKOVÁ Eva ŘIHÁČEK Michal VYSKOČILOVÁ Mária VALÍK Dalibor ELBL Lubomír

Rok publikování 2023
Druh Článek v odborném periodiku
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.frontiersin.org/articles/10.3389/fcvm.2023.1243531/full
Doi http://dx.doi.org/10.3389/fcvm.2023.1243531
Klíčová slova lymphoma; cardiotoxicity; chemotherapy; modern treatment; prevention; cardiac adverse events
Popis Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info